Heart Failure News and Research

RSS

Heart failure (HF) is a condition in which a problem with the structure or function of the heart impairs its ability to supply sufficient blood flow to meet the body's needs. It should not be confused with cardiac arrest or myocardial infarction.

Relypsa completes $70M Series B financing

Relypsa, Inc., a biopharmaceutical company developing non-absorbed polymeric drugs, today announced the completion of a Series B financing totaling $70 million. OrbiMed Advisors, LLC, led the financing with participation from existing Relypsa investors New Leaf Venture Partners, 5AM Ventures, Delphi Ventures, Sprout Group and Mediphase Venture Partners.

13 Sep 2010

Geron, UCS collaborate to develop hESC-derived chondrocytes for cartilage damage, joint disease treatment

Geron Corporation today announced that the company has entered into a collaboration with University Campus Suffolk (UCS) in the U.K. to develop human embryonic stem cell-derived chondrocytes for the treatment of cartilage damage and joint disease.

13 Sep 2010

Geron signs worldwide, exclusive license agreement with University of Edinburgh

Geron Corporation today announced that it has entered into a worldwide, exclusive license agreement with the University of Edinburgh covering technology that allows the efficient production of chondrocytes (cartilage forming cells) from human pluripotent stem cells.

13 Sep 2010

Scientists to present preclinical pharmacology data on TRV120027 at Heart Failure Society of America Meeting

Trevena Inc., the leader in the discovery and development of G-protein coupled receptor biased ligands, today announced that its scientists are presenting two posters featuring compelling preclinical pharmacology data on TRV120027 at the 14th Annual Heart Failure Society of America Meeting being held September 12-15, 2010 in San Diego.

13 Sep 2010

Heart Failure Society of America's 14th Annual Scientific Meeting convenes September 12, 2010

The Heart Failure Society of America (HFSA) 14th Annual Scientific Meeting convened Sunday, September 12, 2010 at the San Diego Convention Center in San Diego. This four-day meeting -- a forum for heart failure specialists to present research findings and advances in treatment -- will address emerging trends in research and new developments in the approach to treating patients with all stages of heart failure.

13 Sep 2010

Amorcyte receives patent for chemotactic hematopoietic stem cell product

Amorcyte, Inc., a biopharmaceutical company developing cell therapy products to treat cardiovascular disease, today announced that it has been granted United States Patent number 7,794,705 titled "Compositions and Methods of Vascular Injury Repair." The patent contains both composition of matter and method claims surrounding therapeutic chemotactic hematopoietic stem cell products used in treating or repairing a vascular injury following an acute myocardial infarction (AMI), and delivery of the cell therapy.

13 Sep 2010

Doctor works to measure outcomes of provider care

Forbes profiles "the most powerful doctor you never heard of," a Yale cardiologist who does "outcomes research" in which he measures "how well doctors are doing in the real world, outside of controlled trials--what they are doing right, what they are doing wrong and what they are forgetting to do entirely."

10 Sep 2010

VCU Pauley Heart Center to investigate portable, mechanical driver for powering artificial hearts

The Virginia Commonwealth University Medical Center is the lead institution in a national clinical trial of technology that will allow artificial heart patients to recuperate, rehabilitate and wait in the comfort of their own homes until a donor heart becomes available for transplant.

10 Sep 2010

UC Denver researcher awarded NIH grant to study PAH

A disease that has no cure in young children and adults is getting closer attention, thanks to a University of Colorado Denver Bioengineering assistant professor and a five year National Heart Lung and Blood Institute/National Institutes of Health grant. Kendall Hunter, PhD, will perform research to improve the diagnosis and prognosis of pulmonary arterial hypertension in children and adults with approximately $700,000 over a five-year period.

10 Sep 2010

Cachexia reduces function and changes muscle structure of heart in mice with colon cancer

The wasting disease associated with some cancers that is typically seen affecting skeletal muscles can also cause significant damage to the heart, new research in mice suggests.

9 Sep 2010

Arcapita enters equity investment, option to purchase agreement with St. Jude Medical

Arcapita, a global investment company, announced today that Atlanta-based CardioMEMS, an Arcapita Ventures portfolio company, has entered into an equity investment and option to purchase agreement with St. Jude Medical, a global medical device company.

9 Sep 2010

St. Jude Medical to invest $60M in CardioMEMS

St. Jude Medical, Inc., a global medical device company, and privately-held CardioMEMS today announced that they have reached an agreement under which St. Jude Medical will make a $60 million equity investment in CardioMEMS, a medical device company that has developed a wireless sensing and communication technology to assess cardiac performance.

7 Sep 2010

Researchers to study protein fragments released into bloodstream after heart attack

A blood test to diagnose which heart attack survivors will suffer heart failure is the goal of a new five-year, $11.6 million contract to the UT Health Science Center San Antonio from the National Heart, Lung, and Blood Institute (NHLBI).

4 Sep 2010

FDA approves IDE study to evaluate HeartWare Ventricular Assist System

HeartWare International, Inc., a leading innovator of less invasive, miniaturized circulatory support technologies that are revolutionizing the treatment of advanced heart failure, today announced that the U.S. Food and Drug Administration (FDA) has approved an IDE (Investigational Device Exemption) Supplement that allows HeartWare to enroll a second allotment of 54 patients in its "ADVANCE" bridge-to-transplant clinical trial under a Continued Access Protocol (CAP).

4 Sep 2010

Cardiogenesis Corporation releases comment on STAR-heart study

Cardiogenesis Corporation, released comments today regarding the STAR-heart study.The STAR-heart study, which was presented at the European Society of Cardiology 2010 Congress in August 2010, reported that the intracoronary injection of autologous stem cells derived from bone marrow is associated with improved hemodynamics and long term survival in the treatment of chronic heart failure.

3 Sep 2010

European Commission approves MSD's MAA for SYCREST in manic episodes associated with bipolar I disorder

MSD announced today that the European Commission has approved the Marketing Authorization Application (MAA) for SYCREST® (asenapine) sublingual tablets for the treatment of moderate to severe manic episodes associated with bipolar I disorder in adults. Today's decision was based on recommendations from the European Medicines Agency (EMA) Committee for Medicinal Products for Human Use (CHMP). The Commission Decision applies to all 27 European Member States.

3 Sep 2010

BRINAVESS IV granted marketing approval in EU for conversion of recent onset AF to sinus rhythm

MSD and Cardiome Pharma Corp. today announced that the intravenous (IV) formulation of BRINAVESS™ (vernakalant) has been granted marketing approval in the European Union (EU), Iceland and Norway for the conversion of recent onset atrial fibrillation (AF) to sinus rhythm in adults.

2 Sep 2010

ESC releases new Clinical Practice Guidelines for management of Grown-up Congenital Heart Disease

The European Society of Cardiology (ESC) today announces the release of new Clinical Practice Guidelines covering the management of Grown-up Congenital Heart Disease (GUCH). More than two million adults in Europe are assumed to be affected by the condition, and the numbers are growing as a consequence of sharply increased survival rates due to advances in paediatric cardiology and heart surgery.

2 Sep 2010

Research finds link between chronic heart failure, iron deficiency

Iron plays a key role in human homeostasis. It is essential for growth and survival, and is a vital ingredient in numerous processes including erythropoiesis, oxygen transport and storage, oxidative metabolism in the skeletal and heart muscle, synthesis and degradation of lipids, carbohydrates, DNA and RNA. Important though it is, iron metabolism must be precisely controlled because iron is insoluble and excess levels can be toxic.

2 Sep 2010

ESC updates Clinical Practice Guidelines on devices for heart failure treatment

The European Society of Cardiology (ESC) today announces a focused update of its Clinical Practice Guidelines covering Device Therapy in Heart Failure. This is the first time that current ESC guidelines have been updated, reflecting the pace of research in this field and the importance of recently published evidence.

2 Sep 2010

Heart Failure News and Research

Further Reading

Relypsa completes $70M Series B financing

Geron, UCS collaborate to develop hESC-derived chondrocytes for cartilage damage, joint disease treatment

Geron signs worldwide, exclusive license agreement with University of Edinburgh

Scientists to present preclinical pharmacology data on TRV120027 at Heart Failure Society of America Meeting

Heart Failure Society of America's 14th Annual Scientific Meeting convenes September 12, 2010

Amorcyte receives patent for chemotactic hematopoietic stem cell product

Doctor works to measure outcomes of provider care

VCU Pauley Heart Center to investigate portable, mechanical driver for powering artificial hearts

UC Denver researcher awarded NIH grant to study PAH

Cachexia reduces function and changes muscle structure of heart in mice with colon cancer

Arcapita enters equity investment, option to purchase agreement with St. Jude Medical

St. Jude Medical to invest $60M in CardioMEMS

Researchers to study protein fragments released into bloodstream after heart attack

FDA approves IDE study to evaluate HeartWare Ventricular Assist System

Cardiogenesis Corporation releases comment on STAR-heart study

European Commission approves MSD's MAA for SYCREST in manic episodes associated with bipolar I disorder

BRINAVESS IV granted marketing approval in EU for conversion of recent onset AF to sinus rhythm

ESC releases new Clinical Practice Guidelines for management of Grown-up Congenital Heart Disease

Research finds link between chronic heart failure, iron deficiency

ESC updates Clinical Practice Guidelines on devices for heart failure treatment

Sensing a Healthier Future

Achieving and maintaining ISO/IEC 27001 and BS 10012 certifications

Expanding research and clinical options for children with cancer

Latest News